Stock Events

Stock Events

Jade Biosciences 

$23.5
45
+$0.65+2.84% Monday 19:55

Statistics

Day High
23.54
Day Low
22.28
52W High
96.95
52W Low
6.76
Volume
528,810
Avg. Volume
-
Mkt Cap
1.08B
P/E Ratio
-
Dividend Yield
-
Dividend
-

Upcoming

Earnings

18MayExpected
Q1 2025
Q2 2025
Q3 2025
Q4 2025
Next
-12.1
-8.21
-4.32
-0.43
Expected EPS
-0.482538
Actual EPS
N/A

Financials

-Profit Margin
Unprofitable
2019
2020
2021
2022
2023
2024
0Revenue
-139.26MNet Income

Analyst Ratings

29.2Average Price Target
The highest estimate is 39.00.
From 5 ratings within the last 6 months. This is not an investment recommendation.
Buy
100%
Hold
0%
Sell
0%

People Also Follow

This list is based on the watchlists of people on Stock Events who follow JBIO. It's not an investment recommendation.

Competitors

This list is an analysis based on recent market events. It's not an investment recommendation.
Vertex Pharmaceuticals
VRTX
Mkt Cap112.22B
Vertex Pharmaceuticals is a competitor because it develops and markets therapies for treating cystic fibrosis, a space where Aerovate Therapeutics is also aiming to innovate with its cardiovascular and pulmonary disease treatments.
Gilead Sciences
GILD
Mkt Cap170.84B
Gilead Sciences is involved in the research and development of drugs for pulmonary diseases among other areas, making it a direct competitor to Aerovate Therapeutics in the pulmonary treatment market.
Arvinas
ARVN
Mkt Cap694.91M
Arvinas, Inc. is focused on developing therapies for cancers and other difficult-to-treat diseases, including lung diseases, which puts it in competition with Aerovate Therapeutics.
Incyte
INCY
Mkt Cap19.47B
Incyte Corporation works on the discovery, development, and commercialization of proprietary therapeutics, including for serious pulmonary conditions, competing with Aerovate Therapeutics.
Galapagos NV
GLPG
Mkt Cap1.97B
Galapagos NV is engaged in the discovery and development of small molecule medicines with novel modes of action, several of which target pulmonary diseases, making it a competitor.
Biomarin Pharmaceutical
BMRN
Mkt Cap10.51B
BioMarin Pharmaceutical Inc. focuses on enzyme replacement therapies and other drug developments for rare genetic diseases, some of which involve pulmonary aspects, competing with Aerovate.
Sarepta Therapeutics
SRPT
Mkt Cap2.26B
Sarepta Therapeutics, Inc. is known for its focus on RNA-targeted therapeutics, including treatments for rare diseases, some of which may overlap with Aerovate Therapeutics' focus areas.
Alnylam Pharmaceuticals
ALNY
Mkt Cap41.32B
Alnylam Pharmaceuticals, Inc. works on RNAi therapeutics for the treatment of rare diseases, including those affecting the lungs, making it a competitor to Aerovate Therapeutics.
Regeneron Pharmaceuticals
REGN
Mkt Cap79.35B
Regeneron Pharmaceuticals, Inc. is a biotechnology company that develops and commercializes medicines for the treatment of serious medical conditions, including pulmonary diseases, competing with Aerovate Therapeutics.

About

Jade Biosciences, Inc. is a biotechnology company focused on developing best-in-class therapies to address critical unmet needs in autoimmune diseases. Their lead asset, JADE-001, targets the anti-A PRoliferation-Inducing Ligand (APRIL) pathway for the treatment of immunoglobulin A (IgA) nephropathy. JADE-001 is anticipated to enter clinical trials in the second half of 2025, with initial data expected in the first half of 2026. The company's pipeline also includes two preclinical antibody programs, JADE-002 and JADE-003.
Show more...
CEO
Mr. Tom Frohlich
Employees
50
Country
United States
ISIN
US0080642061

Listings

XNAS
US
JBIO
BOATS
BOATS
JBIO.BOATS

0 Comments

Share your thoughts

FAQ

What is Jade Biosciences stock price today?▼
The current price of JBIO is $23.5 USD — it has increased by +2.84% in the past 24 hours. Watch Jade Biosciences stock price performance more closely on the chart.
What is Jade Biosciences stock ticker?▼
Depending on the exchange, the stock ticker may vary. For instance, on exchange Jade Biosciences stocks are traded under the ticker JBIO.
Is Jade Biosciences stock price growing?▼
JBIO stock has risen by +20.88% compared to the previous week, the month change is a +68.34% rise, over the last year Jade Biosciences has showed a -75.76% decrease.
What is Jade Biosciences market cap?▼
Today Jade Biosciences has the market capitalization of 1.08B
When is the next Jade Biosciences earnings date?▼
Jade Biosciences is going to release the next earnings report on May 18, 2026.
What were Jade Biosciences earnings last quarter?▼
JBIO earnings for the last quarter are -0.45 USD per share, whereas the estimation was -0.48 USD resulting in a +6.41% surprise. The estimated earnings for the next quarter are N/A USD per share.
What is Jade Biosciences revenue for the last year?▼
Jade Biosciences revenue for the last year amounts to 0 USD.
What is Jade Biosciences net income for the last year?▼
JBIO net income for the last year is -139.26M USD.
How many employees does Jade Biosciences have?▼
As of April 21, 2026, the company has 50 employees.
In which sector is Jade Biosciences located?▼
Jade Biosciences operates in the Health & Wellness sector.
When did Jade Biosciences complete a stock split?▼
The last stock split for Jade Biosciences was on April 29, 2025 with a ratio of 1:35.
Where is Jade Biosciences headquartered?▼
Jade Biosciences is headquartered in Waltham, United States.